Filing Analysis
Regulation FD Disclosure
Filed May 06, 2026
LOW
Tenaya Therapeutics announced its financial results for the first quarter ended March 31, 2026. The filing is a routine disclosure of quarterly performance and includes the earnings press release as an exhibit.
Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Filing dated May 6, 2026
- Triggered Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release
Regulation FD Disclosure
Filed Mar 11, 2026
LOW
Tenaya Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal announcement of these results via a press release attached as Exhibit 99.1.
Key Facts
- The report was filed on March 11, 2026.
- The financial results cover the fiscal quarter and full year ended December 31, 2025.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- The company is classified as an emerging growth company.
Material Agreement
Filed Mar 05, 2026
MEDIUM
Tenaya Therapeutics entered into a multi-target research collaboration with Alnylam Pharmaceuticals to discover and validate novel gene targets for cardiovascular disease. The deal includes an upfront payment of up to $10 million and potential future milestones totaling $1.13 billion.
Red Flags
- Alnylam may unilaterally terminate the agreement in its entirety for any or no reason.
- The upfront payment is relatively small ($10M) compared to the $1.13B headline milestone figure, which is highly contingent on long-term success.
Key Facts
- Agreement signed on March 4, 2026, for a 24-month initial research collaboration period.
- Tenaya and Alnylam will nominate an aggregate of 15 targets for validation.
- Tenaya receives an upfront payment of up to $10.0 million, subject to $500,000 reductions for certain targets not advanced.
- Tenaya is eligible for up to $1.13 billion in aggregate development, regulatory, and sales-based milestones.
- Alnylam will reimburse Tenaya for full-time employees (FTEs) and out-of-pocket costs during the validation phase.
- Alnylam assumes sole responsibility for development, manufacturing, and commercialization after the validation phase.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.